



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

WASHINGTON, D.C. 20231

In re application of:

Robert E. Fischell

Examiner: F. Jaworski

For: Implantable, Programmable Medication Infusion System

Art Unit: 335

Serial No.: 34,155

#18/C/Chase  
4-8-81

Filed: April 27, 1979

RESPONSE UNDER 37 C.F.R. 111

The Hon. Commissioner of Patents and Trademarks  
Washington, D.C. 20231

Dear Sir:

Kindly amend the above-identified case as indicated below:

In the Abstract

Line 4 and line 8, change "(20)" to -- (10) --.

In the Technological Context of the Invention

Page 2, line 7, after "considered.", insert -- Furthermore,

Ellinwood describes a device that causes medication to be dispensed in the body when the bellows pump contracts. The result achieved in the Ellinwood embodiment is discrete pulsatile flow, which has three distinct disadvantages:

1. One cannot maintain a continuous exponentially decaying flow of medication which is required for the treatment of some disorders;
2. The absence of a continuous, controllably decaying outward flow from the pump outlet (such as a catheter) can result, due to the body's functioning, in the clogging of the outlet (or catheter) tip; and
3. The absence of flow resistance or restriction at the output allows the possibility of an inadvertently high medication flow rate into the body in the event of bellows pump runaway. --